Swiss Biotech Nouscom Raises €120 Million Series D to Advance Cancer Immunotherapy for Lynch Syndrome
Swiss biotech Nouscom raised €120 million in a Series D round co‑led by M Ventures and Revelation Partners, bringing its neoantigen‑based immunotherapy platform closer to a registration‑enabling trial for cancer interception in Lynch Syndrome patients.